253 related articles for article (PubMed ID: 35414272)
1. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
Arunachalum S; Velado K; Vigersky RA; Cordero TL
J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
[TBL] [Abstract][Full Text] [Related]
2. Real-world performance of the MiniMed™ 670G system in Europe.
Da Silva J; Bosi E; Jendle J; Arrieta A; Castaneda J; Grossman B; Cordero TL; Shin J; Cohen O
Diabetes Obes Metab; 2021 Aug; 23(8):1942-1949. PubMed ID: 33961340
[TBL] [Abstract][Full Text] [Related]
3. Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users.
Silva JD; Lepore G; Battelino T; Arrieta A; Castañeda J; Grossman B; Shin J; Cohen O
Diabetes Technol Ther; 2022 Feb; 24(2):113-119. PubMed ID: 34524003
[No Abstract] [Full Text] [Related]
4. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317
[No Abstract] [Full Text] [Related]
5. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
[TBL] [Abstract][Full Text] [Related]
6. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
[No Abstract] [Full Text] [Related]
7. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.
Forlenza GP; Ekhlaspour L; DiMeglio LA; Fox LA; Rodriguez H; Shulman DI; Kaiserman KB; Liljenquist DR; Shin J; Lee SW; Buckingham BA
Pediatr Diabetes; 2022 May; 23(3):324-329. PubMed ID: 35001477
[TBL] [Abstract][Full Text] [Related]
8. Safety and Glycemic Outcomes During the MiniMed
Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
[No Abstract] [Full Text] [Related]
9. Six-Month Effectiveness of Advanced
Tornese G; Buzzurro F; Carletti C; Faleschini E; Barbi E
Front Endocrinol (Lausanne); 2021; 12():766314. PubMed ID: 34858339
[TBL] [Abstract][Full Text] [Related]
10. MiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users.
Elbarbary NS; Ismail EAR
Diabetol Metab Syndr; 2023 Oct; 15(1):205. PubMed ID: 37845757
[TBL] [Abstract][Full Text] [Related]
11. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
Grassi B; Gómez AM; Calliari LE; Franco D; Raggio M; Riera F; Castro M; McVean J; van den Heuvel T; Arrieta A; Castañeda J; Cohen O
Diabetes Obes Metab; 2023 Jun; 25(6):1688-1697. PubMed ID: 36789699
[TBL] [Abstract][Full Text] [Related]
12. Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System.
Kesavadev J; Basanth A; Krishnan G; Shankar A; Sanal G; Jothydev S
Diabetes Ther; 2023 Aug; 14(8):1319-1330. PubMed ID: 37278948
[TBL] [Abstract][Full Text] [Related]
13. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
[No Abstract] [Full Text] [Related]
14. Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
Castañeda J; Mathieu C; Aanstoot HJ; Arrieta A; Da Silva J; Shin J; Cohen O
Diabetes Obes Metab; 2022 Nov; 24(11):2212-2221. PubMed ID: 35791621
[TBL] [Abstract][Full Text] [Related]
15. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
Arrieta A; Battelino T; Scaramuzza AE; Da Silva J; Castañeda J; Cordero TL; Shin J; Cohen O
Diabetes Obes Metab; 2022 Jul; 24(7):1370-1379. PubMed ID: 35403792
[TBL] [Abstract][Full Text] [Related]
16. Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems.
Forlenza GP; Dai Z; Niu F; Shin JJ
Diabetes Technol Ther; 2024 Mar; 26(S3):7-16. PubMed ID: 38377321
[No Abstract] [Full Text] [Related]
17. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
[TBL] [Abstract][Full Text] [Related]
18. Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus.
Pei Y; Ke W; Lu J; Lin Y; Zhang Z; Peng Y; Bi Y; Li Y; Hou J; Zhang X; Chen X; Treminio Y; Lee SW; Shin J; Rhinehart AS; Vigersky RA; Mu Y
Diabetes Technol Ther; 2023 Oct; 25(10):718-725. PubMed ID: 37578804
[No Abstract] [Full Text] [Related]
19. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence.
Choudhary P; Arrieta A; van den Heuvel T; Castañeda J; Smaniotto V; Cohen O
Diabetes Technol Ther; 2024 Mar; 26(S3):32-37. PubMed ID: 38377326
[No Abstract] [Full Text] [Related]
20. Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience.
Halim B; Abraham MB; Manos G; Arrieta A; Dai Z; Vogrin S; Lu J; MacIsaac R; Ekinci EI; Davis EA; Jenkins A; Shin J; Vigersky RA; Jones TW; O'Neal D
Diabetes Technol Ther; 2024 Mar; 26(3):190-197. PubMed ID: 38444313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
